All Work

Chris Lange

Halozyme Therapeutics Wins Big on Roche License Agreement

Halozyme Therapeutics saw its shares make a handy gain early on Thursday after the firm announced that it licensed its Enhanze drug-delivery technology to Roche for exclusive development of an “undisclosed therapeutic target.”

Chris Lange · 9 years ago

Wednesday’s Biggest Winners and Losers in the S&P 500

Although the U.S. broad markets ended the day relatively flat, the S&P 500 touched a new all-time high even if just briefly. Also the DJIA and Nasdaq are also within points of their respective…

Chris Lange · 9 years ago

Can Retail Actually Grow Holiday Jobs This Year?

The strength of retail sales in the fourth quarter of each year is a benchmark for how well the U.S. consumer economy is doing. Over the past ten years, the number of jobs added…

Chris Lange · 9 years ago

Short Sellers Hike Bets in Major Biotechs

The August 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.

Chris Lange · 9 years ago

Short Sellers Run for Cover From Major Oil

The August 31 short interest data have been compared with the previous figures, and short interest moves for most of the selected oil stocks were downward.

Chris Lange · 9 years ago

Major Pharma Short Interest Surges

The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.

Chris Lange · 9 years ago

Tuesday’s Biggest Winners and Losers in the S&P 500

Tuesday was another positive day for the U.S. broad markets with all major averages posting a gain. Crude oil was positive on the day and helped lift Oil & Gas stocks. Practically all of…

Chris Lange · 9 years ago

Meet Apple’s Newest iPhone

The Apple 10 year anniversary for the iPhone is underway and we have already seen some incredible developments. Not only is the new Apple campus impressive but the Apple Watch broke the mold as…

Chris Lange · 9 years ago

Sage Therapeutics Gets a Dunce Hat

Sage Therapeutics saw its shares drop by about a quarter early on Tuesday after the firm gave an update on its late-stage study trial in the treatment super-refractory status epilepticus.

Chris Lange · 9 years ago

Monday’s Biggest Winners and Losers in the S&P 500

Monday was an exception day for the U.S. broad markets with all three major indices up. In fact, the market had its best day since earlier March of this year. Crude oil posted a…

Chris Lange · 9 years ago